PSMA靶向放射性药物治疗的最佳患者照护实践
文章基于VISION研究经验及已发表证据与指南,总结转移性去势抵抗性前列腺癌(mCRPC)患者接受[177Lu]Lu-PSMA-617治疗时的不良事件监测管理与辐射安全最佳实践。作者强调多学科协作、患者教育及个体化获益风险评估对优化患者管理的重要性。
要点
- 对疲乏、口干等不良事件及辐射安全原则的充分教育是有效给药和患者预期管理的关键。
- 跨学科医护人员咨询是PSMA靶向放射性药物治疗期间优化患者管理的基石。
- 多学科协作对确保患者安全高效监测管理至关重要,尿失禁时辐射安全尤其具有挑战性。
核心结论
- 提供关于不良事件(如疲乏和口干)和辐射安全原则的充分教育是有效给药和管理患者预期的关键。
- 医护人员跨学科的患者咨询是PSMA靶向放射性药物治疗期间优化患者管理的基石,多学科协作至关重要。
- 医生必须遵守辐射安全规程并向患者提供辐射安全注意事项的咨询。
- [177Lu]Lu-PSMA-617治疗通常耐受性良好,但可能需要剂量调整、药物或输血等额外干预。
- 临床实践中应始终基于个案评估获益风险比。
研究设计与样本
- 作者基于其作为VISION研究研究者的经验,并在全面回顾已发表的关于前列腺癌放射性药物治疗管理与指南的证据后,提供最佳实践指导。
主要发现
- 作者识别出在管理[177Lu]Lu-PSMA-617相关辐射安全与不良事件方面存在教育缺口。
- 提供关于不良事件(如疲乏和口干)和辐射安全原则的充分教育是有效给药和管理患者预期的关键。
- 尿失禁在辐射安全背景下可能具有挑战性。
- 医学肿瘤学家与核医学团队之间的多学科协作可确保患者得到安全高效的监测与管理。
临床怎么用
- 医护人员应跨学科向患者提供咨询,作为PSMA靶向放射性药物治疗期间优化患者管理的基石。
- 医生必须遵守辐射安全规程并向患者提供辐射安全注意事项的咨询。
- 医学肿瘤学家与核医学团队应进行多学科协作,以确保患者得到安全高效的监测与管理。
- 临床实践中应始终基于个案评估获益风险比。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimal patient management protocols for metastatic castration-resistant prostate cancer (mCRPC) are poorly defined and even further complexified with new therapy approvals, such as radiopharmaceuticals. The prostate-specific membrane antigen (PSMA)-targeted agent 177Lu vipivotide tetraxetan ([177Lu]Lu-PSMA-617), approved after the phase III VISION study, presents physicians with additional aspects of patient management, including specific adverse event (AE) monitoring and management, as well as radiation safety. Drawing on our experience as VISION study investigators, here we provide guidance on best practices for delivering PSMA-targeted radiopharmaceutical therapy (RPT) to patients with mCRPC. After a comprehensive review of published evidence and guidelines on RPT management in prostate cancer, we identified educational gaps in managing the radiation safety and AEs associated with [177Lu]Lu-PSMA-617. Our results showed that providing sufficient education on AEs (e.g., fatigue and dry mouth) and radiation safety principles is key to effective delivery and management of patient expectations. Patient counseling by health care professionals, across disciplines, is a cornerstone of optimal patient management during PSMA-targeted RPT. Multidisciplinary collaboration is crucial, and physicians must adhere to radiation safety protocols and counsel patients on radiation safety considerations. Treatment with [177Lu]Lu-PSMA-617 is generally well tolerated; however, additional interventions may be required, such as dosing modification, medications, or transfusions. Urinary incontinence can be challenging in the context of radiation safety. Multidisciplinary collaboration between medical oncologists and nuclear medicine teams ensures that patients are monitored and managed safely and efficiently. In clinical practice, the benefit-to-risk ratio should always be evaluated on a case-by-case basis.
引用
- Calais J, Morris MJ, Kendi AT, et al. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2024. PMID: 39362764. doi:10.2967/jnumed.124.268363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。